Theseus Pharmaceuticals Inc (THRX) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access THRX Annual Balance Sheets →
The data below summarizes Theseus Pharmaceuticals Inc's balance sheet position from Sep 30 2022 to Sep 30 2023, enabling a period-by-period comparison of financial strength.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2023)
(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Assets
Cash & cash equivalent46.89
Available-for-sale Securities, Debt Securities, Current MA158.23
Cash & Short-term Investments204.00
Prepaid Expense And Other Assets Current4.46
Total Current Assets209.59
Equipment/Property/Plant Net0.41
Long-term investments20.31
Other Assets, Noncurrent2.00
Operating Lease Right Of Use Asset3.92
Total Assets234.63
Liabilities
Accounts Payable, Current AC1.31
Accrued Liabilities, Current AC4.93
Other Liabilities, Current0.76
Total Current Liabilities7.00
Total Long-term Debt0.00
Other liabilities, Noncurrent3.10
RestrictedStockLiabilityNoncurrent0.21
Operating Lease Liability Current0.76
Total Liabilities10.11
Stockholders' Equity
Common Stock Value0.00
Additional Paid In Capital Common Stock379.94
Retained Earnings / Accumulated Deficit-155.08
Other Equity-0.35
Common Stockholder's Equity224.52
Total Stockholder's Equity224.52
Liabilities & Stockholder's Equity234.63
4 historic quarters locked

Sign in to unlock the full Theseus Pharmaceuticals Inc balance sheet history.

About Theseus Pharmaceuticals Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001745020-23-000080

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.